28,267 Shares in Intra-Cellular Therapies Inc (ITCI) Purchased by Two Sigma Advisers LP

Two Sigma Advisers LP acquired a new position in Intra-Cellular Therapies Inc (NASDAQ:ITCI) in the fourth quarter, Holdings Channel reports. The firm acquired 28,267 shares of the biopharmaceutical company’s stock, valued at approximately $322,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. raised its stake in Intra-Cellular Therapies by 1.9% during the 4th quarter. BlackRock Inc. now owns 4,004,666 shares of the biopharmaceutical company’s stock valued at $45,614,000 after buying an additional 76,356 shares during the last quarter. Vanguard Group Inc raised its stake in Intra-Cellular Therapies by 1.8% during the 3rd quarter. Vanguard Group Inc now owns 3,943,792 shares of the biopharmaceutical company’s stock valued at $85,580,000 after buying an additional 69,950 shares during the last quarter. Vanguard Group Inc. raised its stake in Intra-Cellular Therapies by 1.8% during the 3rd quarter. Vanguard Group Inc. now owns 3,943,792 shares of the biopharmaceutical company’s stock valued at $85,580,000 after buying an additional 69,950 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Intra-Cellular Therapies by 1.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,444,223 shares of the biopharmaceutical company’s stock valued at $16,450,000 after buying an additional 24,335 shares during the last quarter. Finally, Samlyn Capital LLC raised its stake in Intra-Cellular Therapies by 64.2% during the 4th quarter. Samlyn Capital LLC now owns 1,266,138 shares of the biopharmaceutical company’s stock valued at $14,421,000 after buying an additional 494,918 shares during the last quarter. Institutional investors own 68.88% of the company’s stock.

Shares of ITCI stock opened at $12.93 on Wednesday. Intra-Cellular Therapies Inc has a 1 year low of $10.21 and a 1 year high of $23.64. The firm has a market cap of $687.86 million, a PE ratio of -4.55 and a beta of 1.38.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings data on Wednesday, February 27th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.16. On average, sell-side analysts forecast that Intra-Cellular Therapies Inc will post -4.05 earnings per share for the current year.

A number of equities research analysts have weighed in on ITCI shares. Zacks Investment Research lowered shares of Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a research note on Thursday, January 10th. ValuEngine downgraded shares of Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a research report on Thursday, January 24th. BidaskClub raised shares of Intra-Cellular Therapies from a “strong sell” rating to a “sell” rating in a research report on Saturday, February 2nd. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $26.00 price objective on shares of Intra-Cellular Therapies in a research report on Monday, April 15th. Two analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $27.00.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.baseballdailydigest.com/news/2019/04/24/28267-shares-in-intra-cellular-therapies-inc-itci-purchased-by-two-sigma-advisers-lp.html.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases.

Further Reading: Market Capitalization – What it Means for Investors

Want to see what other hedge funds are holding ITCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intra-Cellular Therapies Inc (NASDAQ:ITCI).

Institutional Ownership by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.